



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



**ACT-709478**

Item No. 25371

**CAS Registry No.:** 1838651-58-3  
**Formal Name:** N-[1-[(5-cyano-2-pyridinyl)methyl]-1H-pyrazol-3-yl]-4-[1-(trifluoromethyl)cyclopropyl]-benzeneacetamide

**MF:** C<sub>22</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O

**FW:** 425.4


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 220 nm

**Supplied as:** A solid

**Storage:** -20°C

**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

ACT-709478 is supplied as a solid. A stock solution may be made by dissolving the ACT-709478 in the solvent of choice, which should be purged with an inert gas. ACT-709478 is soluble in DMSO.

## Description

ACT-709478 is an inhibitor of T-type voltage-gated calcium channel 3.1 (Ca<sub>v</sub>3.1), Ca<sub>v</sub>3.2, and Ca<sub>v</sub>3.3 (IC<sub>50</sub>s = 6.4, 18, and 7.5 nM, respectively).<sup>1</sup> It is selective for T-type calcium channels over the L-type calcium channel Ca<sub>v</sub>1.2 (IC<sub>50</sub> = 2,410 nM). ACT-701478 (10 mg/kg) reduces the cumulative duration of absence-like seizures in rats. It also reduces the severity of seizures in a rat model of audiogenic seizures when administered at a dose of 100 mg/kg.

## Reference

1. Bezençon, O., Heidmann, B., Siegrist, R., *et al.* Discovery of a potent, selective T-type calcium channel blocker as a drug candidate for the treatment of generalized epilepsies. *J. Med. Chem.* **60(23)**, 9769-9789 (2017).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/08/2021

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM